In contrast, many previous studies utilizing CCR5 inhibitors have employed models of moderate to severe TBI (< CGS12), ischemic stroke, or chronic neurodegenerative diseases such as Alzheimer’s disease (AD) [24, 26, 34–39]. This evidence concerns the gene CCR5 and ischemic stroke.